Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 390,184
  • Shares Outstanding, K 108,990
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 1.60
  • Price/Sales 14.61
  • Price/Cash Flow N/A
  • Price/Book 4.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.14 +14.01%
on 11/28/18
4.17 -14.15%
on 11/08/18
-0.45 (-11.17%)
since 11/07/18
3-Month
3.14 +14.01%
on 11/28/18
6.18 -42.07%
on 09/11/18
-2.47 (-40.83%)
since 09/07/18
52-Week
1.27 +181.89%
on 12/13/17
7.21 -50.35%
on 07/09/18
+2.06 (+135.53%)
since 12/07/17

Most Recent Stories

More News
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company's Phase 1 dose escalation study...

ARQL : 3.58 (-4.53%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60th American Society of Hematology...

ARQL : 3.58 (-4.53%)
ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November...

ARQL : 3.58 (-4.53%)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 3.58 (-4.53%)
ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present...

ARQL : 3.58 (-4.53%)
ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical data on the company's next generation AKT inhibitor, ARQ 751, in three poster presentations...

ARQL : 3.58 (-4.53%)
ArQule (ARQL) Reports Q3 Loss, Tops Revenue Estimates

ArQule (ARQL) delivered earnings and revenue surprises of 16.67% and 104.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ARQL : 3.58 (-4.53%)
ArQule Reports Third Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018.

ARQL : 3.58 (-4.53%)
New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER),...

ADT : 7.45 (-2.87%)
ARQL : 3.58 (-4.53%)
TRQ : 1.74 (-1.14%)
VIVO : 18.35 (-0.76%)
TIER : 23.30 (-0.34%)
GLRE : 10.16 (-0.29%)
ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG)...

ARQL : 3.58 (-4.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 3.85
1st Resistance Point 3.72
Last Price 3.58
1st Support Level 3.51
2nd Support Level 3.43

See More

52-Week High 7.21
Fibonacci 61.8% 4.94
Fibonacci 50% 4.24
Last Price 3.58
Fibonacci 38.2% 3.54
52-Week Low 1.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar